ARGX argenx NV ADR

$596.20

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending 2025-03-31
Expected on May 07, 2025
The Whisper Number
—
TWN v0.14

About argenx NV ADR

argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.

Website: https://argenx.com

Sector
LIFE SCIENCES
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1697862
Address
INDUSTRIEPARK ZQIJNAARDE 7, BUILDING C B-9052, ZWIJNAARDE, BE
Valuation
Market Cap
$36.47B
P/E Ratio
46.72
PEG Ratio
0.00
Price to Book
6.62
Performance
EPS
$12.76
Dividend Yield
—
Profit Margin
37.00%
ROE
17.40%
Technicals
50D MA
$607.30
200D MA
$573.79
52W High
$678.21
52W Low
$352.77
Fundamentals
Shares Outstanding
61M
Target Price
$779.49
Beta
0.20

ARGX EPS Estimates vs Actual

● Estimated
● Actual

ARGX News & Sentiment

Apr 18, 2025 • Benzinga SOMEWHAT-BULLISH
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years - argenx ( NASDAQ:ARGX )
argenx ARGX has outperformed the market over the past 5 years by 18.91% on an annualized basis producing an average annual return of 32.94%. Currently, argenx has a market capitalization of $36.40 billion.
Apr 15, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Argenx ( ARGX ) Moves 4.4% Higher: Will This Strength Last?
Argenx (ARGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Apr 11, 2025 • Benzinga BULLISH
FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting - argenx ( NASDAQ:ARGX )
FDA approved Vyvgart Hytrulo prefilled syringe for gMG and CIDP self-injection in 20-30 seconds. Human factor studies showed patients and caregivers safely administered the new formulation. China's new tariffs just reignited the same market patterns that led to triple- and quadruple-digit wins ...
Apr 11, 2025 • Benzinga NEUTRAL
Why Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket - argenx ( NASDAQ:ARGX ) , AlTi Global ( NASDAQ:ALTI )
Shares of argenx SE ARGX rose sharply in today's pre-market trading after the company announced the FDA approval of VYVGART Hytrulo prefilled syringe for self-injection in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. argenx shares jumped 5.1% to $573.88 in ...
Apr 09, 2025 • Benzinga NEUTRAL
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline - Eli Lilly ( NYSE:LLY ) , Pfizer ( NYSE:PFE )
India supplies nearly 50% of U.S. generic drugs; tariffs could disrupt $13 billion in exports. A Section 232 probe may delay pharma tariffs until late 2025 or beyond. Wall Street veteran Chris Capre is going live April 9 at 6 PM ET to reveal a short-term strategy that just returned 195%-in the ...
Apr 08, 2025 • Benzinga SOMEWHAT-BULLISH
Argenx's Flagship Drug Vyvgart Shows Sustained Disease Control In Rare Neuromuscular Disease Patients - argenx ( NASDAQ:ARGX )
75% of gMG patients on Vyvgart showed sustained MG-ADL improvements over 126 weeks. Vyvgart Hytrulo improved functional and QoL scores in gMG and CIDP with no rise in infections over nine treatment cycles. With stocks plunging, steady income is key.
Sentiment Snapshot

Average Sentiment Score:

0.260
50 articles with scored sentiment

Overall Sentiment:

Bullish

ARGX Reported Earnings

Financials